



Novartis AG (NVS)

Updated January 30th, 2021 by Nathan Parsh

Key Metrics

Current Price:	\$89	5 Year CAGR Estimate:	10.0%	Market Cap:	\$204 billion
Fair Value Price:	\$102	5 Year Growth Estimate:	4.0%	Ex-Dividend Date	3/4/2021
% Fair Value:	87%	5 Year Valuation Multiple Estimate:	2.8%	Dividend Payment Date:	3/15/2021
Dividend Yield:	3.8%	5 Year Price Target	\$125	Years Of Dividend Growth:	25 ¹
Dividend Risk Score:	B	Retirement Suitability Score:	B	Last Dividend Increase:	1.7% ²

Overview & Current Events

Novartis researches, develops and markets products to improve patients' health. The company's Innovative Medicines division offers medicines in the areas of oncology, cardiovascular, dermatology, respiratory and several others. Novartis Sandoz division markets generic drugs. Novartis employs 109,000 people and has annual sales of more than \$52 billion. Novartis is incorporated in Switzerland, but U.S. investors have access to the company through an American Depositary Receipt, or ADR. There are more than 250 ADRs listed on the New York Stock Exchange, with NVS being one example.

Novartis reported fourth quarter and full year results 1/26/2021. All figures in U.S. dollars. The company's earnings-per-share of \$1.34 was a 1.5% increase from the prior year but \$0.05 lower than expected. Revenue improved 3% to \$12.8 billion, but missed estimates by \$104 million. For the year, earnings-per-share grew 9.5% to \$5.78, \$0.06 ahead of our estimates. Revenue grew 2.6% to \$48.7 billion.

All figures in constant currency. Innovative Medicines grew 1% for the quarter as 6% volume growth was nearly offset by pricing pressure due to generic competition. *Cosentyx*, which treats plaque psoriasis and is the company's top selling product, continues to perform well, producing 13% growth year-over-year even as there were fewer new patients starts related to COVID-19. *Entresto*, which is used to treat chronic heart failure, was higher by 45% to \$632 million due to higher patient market share. The Heart Failure Association of the European Society of Cardiology published a report in early 2019 in which *Entresto* is recommended as a first line treatment option for patients with systolic heart failure. Sales for *Tafinlar + Mekinist*, which treats melanoma, were up 13% due to higher demand in adjuvant melanoma. Sales for *Promacta/Revolade*, which helps lower the risk of bleeding, grew 23% as the product is now a first-line treatment in the U.S. *Kymriah*, used to treat patients with acute lymphoblastic leukemia that have relapsed, was up 42% due to expanded coverage in the U.S., Europe and Japan. *Kymriah* was approved in the U.S. in 2017 for treatment of patients up to 25 years old and is now approved in 27 countries. Sandoz sales were flat as pricing pressure offset volume growth. We expect Novartis to produce earnings-per-share of \$6.40 in 2021.

Growth on a Per-Share Basis

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2026
EPS	\$3.78	\$3.89	\$3.70	\$4.13	\$2.92	\$2.82	\$3.28	\$5.14	\$5.28	\$5.78	\$6.40	\$7.79
DPS	\$2.36	\$2.41	\$2.43	\$2.76	\$2.67	\$2.72	\$2.72	\$2.94	\$2.57	\$3.09	\$3.38	\$4.11
Shares³	2422	2472	2426	2399	2374	2374	2318	2300	2230	2254	2254	2230

Novartis increased earnings at a rate of 4.3% per year from 2011 through 2020; earnings actually grew during the last recession. Healthcare companies often perform well during recessions as people will seek out treatments for ailments regardless of the economic climate. Due to continued strength of the company's top selling products, we are reiterating our expect earnings-per-share annual growth rate of 4%.

¹ In local currency

² In local currency

³ Share count in millions

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



Novartis AG (NVS)

Updated January 30th, 2021 by Nathan Parsh

Novartis pays an annual dividend, with the most recent announcement stating the company is increasing its 2021 dividend 1.7% to \$3.38 in USD. The company has increased its dividend 25 consecutive years in local currency. The dividend for U.S. investors was maintained in 2016 and 2017 after being cut slightly in 2015 due to currency exchange. Dividends are declared in Swiss Francs.

Valuation Analysis

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	Now	2026
Avg. P/E	15.2	14.8	19.8	21.4	33.3	27.3	24.5	16.3	17.9	16.3	13.9	16.0
Avg. Yld.	4.1%	4.2%	3.3%	3.1%	2.7%	3.5%	3.4%	3.4%	2.7%	3.3%	3.8%	3.3%

Novartis saw earnings-per-share decline at the same time the share price accelerated in the 2013-2015 period. We assign shares a fair value price-to-earnings multiple of 16 to help account for the wide variance in valuations over the last decade. This valuation is a premium to most peers, but we feel that the growth in the company's key products, as well as the expectation for new products to produce strong results, warrants the slight premium. Based off estimates for 2021, Novartis has a valuation of 13.9 times earnings. If shares were to reach our target by 2026, then valuation could add 2.8% to annual returns over this time period.

Safety, Quality, Competitive Advantage, & Recession Resiliency


Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2026
Payout	62%	62%	66%	67%	91%	97%	83%	57%	49%	53%	53%	53%

The chief competitive advantage for Novartis is its Innovative Medicines division, which has shown impressive growth over the last year. Four different products have reached the \$1 billion annual sales mark. Another key advantage for the company is Novartis' willingness to spend on research and development. The company spent more than \$9 billion on R&D over the last year. This level of R&D spending should pay off as Novartis expects to bring to market 14 different products over the next two years with the potential for at least a billion dollars in peak sales.

Final Thoughts & Recommendation

Novartis is now expected to return 10% annually through 2026, up from our prior estimate of 8.1%. Even with COVID-19 headwinds for certain products, Novartis still turned in solid growth for the quarter and year. Generic competition remains an issue as well, but the company has several newer products already experiencing high uptake rates. We believe that these products will be the growth engine for Novartis in the coming years. We have increased our five-year price target \$14 to \$125 and maintain our buy rating on shares of Novartis.

Total Return Breakdown by Year



[Click here to rate and review this research report. Your feedback is important to us.](#)

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



Novartis AG (NVS)

Updated January 30th, 2021 by Nathan Parsh

Income Statement Metrics

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Revenue	59,375	51,971	52,716	53,634	50,387	49,436	43,404	46,099	48,677	49,898
Gross Profit	40,392	36,105	36,137	36,289	32,983	31,916	29,771	31,589	34,252	34,777
Gross Margin	68.0%	69.5%	68.6%	67.7%	65.5%	64.6%	68.6%	68.5%	70.4%	69.7%
SG&A Exp.	18,049	15,117	15,241	14,993	14,247	14,192	12,465	13,717	14,369	14,197
D&A Exp.	5,788	4,442	4,405	4,682	5,471	6,043	4,736	5,211	5,826	6,464
Operating Profit	10,780	11,507	10,983	11,089	8,977	8,268	8,702	8,403	9,086	10,152
Op. Margin	18.2%	22.1%	20.8%	20.7%	17.8%	16.7%	20.0%	18.2%	18.7%	20.3%
Net Profit	8,940	9,270	9,175	10,210	17,783	6,712	7,703	12,611	11,732	8,072
Net Margin	15.1%	17.8%	17.4%	19.0%	35.3%	13.6%	17.7%	27.4%	24.1%	16.2%
Free Cash Flow	11,922	11,422	9,796	10,493	8,392	8,596	10,327	11,726	12,225	11,153
Income Tax	1,483	1,706	1,498	1,545	1,106	1,119	1,603	1,295	1,793	1,807

Balance Sheet Metrics

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Total Assets (\$B)	117.50	124.19	126.25	125.39	131.56	130.12	133.08	145.56	118.37	132.06
Cash & Equivalents	3,709	5,552	6,687	13,023	4,674	7,007	8,860	13,271	11,173	11,267
Acc. Receivable	10,323	10,051	9,902	8,275	8,180	8,202	8,600	8,727	8,301	8,217
Inventories	5,930	6,744	7,267	6,093	6,226	6,255	6,867	6,956	6,092	7,242
Goodwill & Int.	61,912	61,421	58,867	53,143	65,391	62,320	61,747	74,013	55,311	66,808
Total Liabilities	51,556	54,928	51,782	54,543	54,434	55,233	58,852	66,871	62,819	75,393
Accounts Payable	4,989	5,593	6,148	5,419	5,668	4,873	5,169	5,556	5,424	5,403
Long-Term Debt	20,229	19,726	17,915	20,359	21,901	23,686	28,425	32,090	27,199	35,850
Total Equity	65,844	69,137	74,343	70,766	77,046	74,832	74,168	78,614	55,474	56,598
D/E Ratio	0.31	0.29	0.24	0.29	0.28	0.32	0.38	0.41	0.49	0.63

Profitability & Per Share Metrics

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Return on Assets	7.4%	7.7%	7.3%	8.1%	13.8%	5.1%	5.9%	9.1%	8.9%	6.4%
Return on Equity	13.9%	13.7%	12.8%	14.1%	24.1%	8.8%	10.3%	16.5%	17.5%	14.4%
ROIC	10.0%	10.6%	10.1%	11.1%	18.7%	6.8%	7.7%	11.8%	12.1%	9.2%
Shares Out.	2422	2472	2426	2399	2374	2374	2318	2300	2230	2254
Revenue/Share	24.61	21.26	21.27	21.71	20.67	20.60	18.31	19.67	20.99	21.73
FCF/Share	4.94	4.67	3.95	4.25	3.44	3.58	4.36	5.00	5.27	4.86

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.